



Hepatitis Vaccines

Sharon Frey, MD

Chair, Hepatitis Vaccines Work Group

Advisory Committee on Immunization Practices
February 27, 2020

ACIP Hepatitis WG Term of Reference

- **Hepatitis B**

- Update the recommendations for HepB vaccination among U.S. adults

Current Recommendations Published Since 2008

- Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant. MMWR April 20, 2018;67:455–458.
- Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR, January 12, 2018;67(No. RR-1):1–31

Work Group Considerations

■ September 2019 - November 2019

- Meetings focused on:
 - Developing the PICO question
 - Estimating denominators of risk groups

■ January 2020

- Presentation of interim results of post-marketing surveillance study, given by principal investigator (Kaiser Permanent Southern California)

■ Prepare for discussion, Spring 2020

- Discussion of the cost-effectiveness analysis (CEA)
- CEA is currently under ACIP technical review (external to the work group)

Policy question under discussion: Should a routine universal HepB-vaccination strategy (2-dose and 3-dose schedules) be utilized vs. the current risk based vaccination strategy (2-dose and 3-dose) for adults?

Population	Adults
Intervention	Universal vaccination strategy
Comparison	Current risk based vaccination strategy
Outcomes of interest	<ul style="list-style-type: none">▪ Mortality▪ Morbidity▪ Incidence▪ Vaccine uptake▪ Seroprotection▪ Adverse events (mild and serious)

Next Steps

- **Continue deliberations on updates to adult hepatitis B vaccination**
 - Complete the CEA review process and present the CEA to the Work Group
 - Discuss the final results of the post-marketing surveillance study for HEPLISAV-B, when available
 - Initiate the GRADE and Evaluation to Recommendation framework (EtR) for universal adult hepatitis B vaccination

Hepatitis Work Group Members

ACIP Members

Sharon Frey (Chair)

José Romero

Liaison Representatives

Elizabeth Barnett (AAP)

Susan Even (ACHA)

Christine Finley (AIM)

Brenna Hughes (ACOG)

Susan Lett (CSTE)

Pamela Rockwell (AAFP)

David Weber (SHEA)

Matthew Zahn (NACCHO)

Ex Officio Member

Marian Major (FDA)

Darcie Everett (FDA)

Consultants

Sharon Balter (LA-DPH)

Robert Frenck (CCHMC)

Kathleen Harriman (CDPH)

Brian McMahon (ANTHC)

Kelly Moore (VUSM)

David Nace (AMDA)

Jennifer Rosen (NYC-DOH)

Ann Thomas (OR-DHS/OHA)

Jennifer Zipprich (MDPH)

Lead

Mark Weng

(CDC/Division of Viral Hepatitis)

Acknowledgements

- **NCHHSTP/Division of Viral Hepatitis**
- **NCIRD/Immunization Services Division**
- **Doug Campos-Outcalt**
- **Rebecca Morgan**
 - GRADE and Evidence to Recommendation framework
- **Food and Drug Administration**

- **CDC subject matter experts**

Mona Doshani

Jeff Nemhauser

Penina Haber

Tina Objio

Aaron Harris

Priti Patel

Beth Hibbs

Sarah Schillie

Megan Hofmeister

Tom Shimabukuro

Andrew Kroger

Phil Spradling

Noele Nelson

Tureka Watson

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

